ArticleIntensive care medicine2020
One-year mortality among non-surgical patients with hematological malignancies admitted to the intensive care unit: a Danish nationwide population-based cohort study.
Article in Intensive care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Temporal trends and prognostic factors in critically ill adult patients with acute leukemia: an individual participant data meta-analysis.Intensive care medicine · 2026Pooled it
- Mortality-Related Risk Factors in Patients with Hematologic Neoplasm Admitted to the Intensive Care Unit: A Systematic Review.Current oncology (Toronto, Ont.) · 2025Pooled it
- A comparative study of intravenous polymyxin B and colistimethate sodium on efficacy, safety, and cost comparison in treating pulmonary infections: a retrospective cohort study.Frontiers in pharmacology · 2026Article
- Factors associated with treatment resumption and long-term outcomes after ICU discharge in patients with hematological malignancies.Annals of intensive care · 2026Article
- Article
- Acute respiratory distress syndrome in patients with cancer: the YELENNA prospective multinational observational cohort study.Intensive care medicine · 2025Observational
- Trends and outcomes of chemotherapy timing in critically ill patients with hematologic malignancies using a Japanese national database.Scientific reports · 2025Article
- Clinical characteristics and prognostic factors of sepsis in patients with malignancy.Scientific reports · 2025Observational
- Development and Validation of a Prediction Model for 1-Year Mortality in Patients With a Hematologic Malignancy Admitted to the ICU.Critical care explorations · 2024Article
- Long-term survival and functional outcomes of critically ill patients with hematologic malignancies: a Canadian multicenter prospective study.Intensive care medicine · 2024Observational
- Demystifying the oncologic patient in the intensive care unit.Critical care science · 2024Article
- Lower versus higher oxygenation targets in ICU patients with haematological malignancy - insights from the HOT-ICU trial.BJA open · 2022Article
- Development and validation of a new risk scoring system for solid tumor patients with suspected infection.Scientific reports · 2022Article
- Preempting critical care services for patients with hematological malignancies.Intensive care medicine · 2021Article
- [Cancer patients in the intensive care unit].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeContemporary data on mortality of hematological patients admitted to the intensive care unit (ICU) are missing. In a Danish nationwide set-up, we assessed 30-day and 1-year mortality in this population including impact of age and comorbidity, with non-hematological patients as reference.
methodsThis population-based cohort study included all non-surgical patients > 15 years of age admitted to an ICU in Denmark between 2010 and 2015. Data on hematological malignancies were obtained from the Danish Hematological Database, and information on the Charlson Comorbidity Index was obtained from the Danish National Patient Registry. Thirty-day and 1-year mortality was estimated using the Kaplan-Meier method. We used Cox proportional hazards regression to estimate hazard ratios.
resultsWe included 2122 ICU patients with a hematological malignancy and 88,951 non-hematological ICU patients. The 30-day mortality was 44% (95% confidence interval: 42-47%) among hematological patients and 27% (27-27%) among non-hematological patients. Similarly, 1-year mortality was 66% (64-68%) and 37% (37-37%), respectively. The corresponding hazard ratio with adjustment for age, sex, and comorbidity was 1.62 (1.54-1.71). Excess mortality was observed in all subgroups of age or of comorbidity. For example, the 1-year mortality for patients with Charlson Comorbidity Index Score > 3: 70% (66-74%) among hematological patients and 62% (61-63%) among non-hematological patients.
conclusionICU patients with hematological malignancy had higher mortality than other ICU patients. However, one third of critically ill patients with a hematological malignancy is alive 1 year after ICU admission.
Indexed as
Identifiers
32072301What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.